

Nucleotides

Outline

- 27.1 Nucleotide Biosynthesis
- 27.2 The Biosynthesis of Purines
- 27.3 Purine Salvage
- 27.4 Purine Degradation
- 27.5 Biosynthesis of Pyrimidines
- 27.6 Pyrimidine Degradation
- 27.7 Deoxyribonucleotide Biosynthesis
- 27.8 Synthesis of Thymine Nucleotides

Nucleotide Biosynthesis

- Nearly all organisms synthesize purines and pyrimidines "de novo"
- Many organisms also "salvage" purines and pyrimidines from diet and degradative pathways
- Ribose generates energy, but purine and pyrimidine rings do not
- Nucleotide synthesis pathways are good targets for anti-cancer/antibacterial strategies


27.2 Biosynthesis of Purines

John Buchanan (1948) "traced" the sources of all nine atoms of purine ring

- N-1: aspartic acid
- N-3, N-9: glutamine
- C-4, C-5, N-7: glycine
- C-6: CO₂
- C-2, C-8: THF - one carbon units

Biochemistry 2/e - Garrett & Grisham

Garrett & Grisham: Biochemistry, 2/e
Figure 27.2




Saunders College Publishing

Inosine-5'-P Biosynthesis

The purine ring is built on a ribose-5-P foundation

- First step: ribose-5-P must be **activated** - by PP_i
- PRPP is limiting substance for purine synthesis
- But PRPP is a branch point so next step is the **committed step - Gln PRPP amidotransferase**
- Note that second step changes C-1 configuration
- G- and A-nucleotides inhibit this step - but at distinct sites!
- Azaserine - Gln analog - inhibitor/anti-tumor


Biochemistry 2/e - Garrett & Grisham



Steps 3-5

- **Step 3:** Glycine carboxyl condenses with amine
 - Glycine carboxyl activated by -P from ATP
 - Amine attacks glycine carboxyl
- **Step 4:** Formyl group of N¹⁰-formyl-THF is transferred to free amino group of GAR
- **Step 5:** C-4 carbonyl forms a P-ester from ATP and active NH₃ attacks C-4 to form imine

Biochemistry 2/e - Garrett & Grisham



Steps 6-8

Closure of the first ring, carboxylation and attack by aspartate

- **Step 6:** Similar in some ways to step 5. ATP activates the formyl group by phosphorylation, facilitating attack by N.
- **Step 7:** Carboxylation probably involves electron "push" from the amino group
- **Step 8:** Attack by the amino group of aspartate links this amino acid with the carboxyl group


Steps 9-11

Loss of fumarate, another 1-C unit and the second ring closure


- Step 9: Deprotonation of Asp-CH₂ leads to cleavage to form fumarate
- Step 10: Another 1-C addition catalyzed by THF
- Step 11: Amino group attacks formyl group to close the second ring
- Note that 5 steps use ATP, but that this is really **six ATP equivalents!**
- Dependence on THF in two steps means that **methotrexate** and **sulfonamides** block purine synthesis

Garrett & Grisham: Biochemistry, 2/e
Figure 27.4



Azaserine



Glutamine



Garrett & Grisham: Biochemistry, 2/e
 Figure 27.5




Making AMP and GMP


Reciprocal control occurs in two ways - see Figures 27.6 and 27.7

- **GTP** is the energy input for AMP synthesis, whereas **ATP** is energy input for GMP
- AMP is made by **N addition from aspartate** (in the familiar way - see Figure 27.6)
- GMP is made by **oxidation at C-2**, followed by replacement of the O by N (from Gln)
- Last step of GMP synthesis is identical to the first two steps of IMP synthesis

Garrett & Grisham: Biochemistry, 2/e
Figure 27.6





Garrett & Grisham: Biochemistry, 2/e
Figure 27.7



Purine Salvage

and Lesch-Nyhan syndrome


- Salvage pathways collect **hypoxanthine** and **guanine** and recombine them with PRPP to form nucleotides in the HGPRT reaction
- **Absence of HGPRT** is cause of Lesch-Nyhan syndrome
- In L-N, purine synthesis is increased 200-fold and uric acid is elevated in blood
- This increase may be due to PRPP feed-forward activation of *de novo* pathways




Purine Degradation

Purine catabolism leads to uric acid (see Figure 27.9)


- Nucleotidases and nucleosidases release ribose and phosphates and leave free bases
- Xanthine oxidase and guanine deaminase route everything to **xanthine**
- Xanthine oxidase converts xanthine to **uric acid**
- Note that xanthine oxidase can oxidize two different sites on the purine ring system



Garrett & Grisham: Biochemistry, 2/e
Figure 27.10







Garrett & Grisham: Biochemistry, 2/e
Figure 27.11




Xanthine Oxidase and Gout

- XO in liver, intestines (and milk) can oxidize hypoxanthine (twice) to uric acid
- Humans and other primates excrete uric acid in the urine, but **most N goes out as urea**
- Birds, reptiles and insects excrete **uric acid** and for them it is the **major nitrogen excretory compound**
- Gout occurs from accumulation of uric acid crystals in the extremities
- **Allopurinol**, which inhibits XO, is a treatment






Allopurinol




Hypoxanthine



Pyrimidine Biosynthesis

- In contrast to purines, **pyrimidines** are not synthesized as nucleotides
- Rather, the pyrimidine ring is completed before a ribose-5-P is added
- **Carbamoyl-P** and **aspartate** are the precursors of the six atoms of the pyrimidine ring

Garrett & Grisham: Biochemistry, 2/e
Figure 27.15




Saunders College Publishing

CPS II

- Carbamoyl phosphate for pyrimidine synthesis is made by **carbamoyl phosphate synthetase II (CPS II)**
- This is a cytosolic enzyme (whereas CPS I is mitochondrial and used for the urea cycle)
- Substrates are **HCO_3^- , glutamine, 2 ATP**
- See Figure 27.16

Garrett & Grisham: Biochemistry, 2/e
 Figure 27.16




de novo Pyrimidine Synthesis

- Aspartate transcarbamoylase (ATCase) catalyzes the condensation of carbamoyl phosphate with aspartate to form carbamoyl-aspartate
- Note that carbamoyl phosphate represents an 'activated' carbamoyl group

More Pyrimidine Synthesis

- Step 3: ring closure and dehydration - catalyzed by **dihydroorotase**
- Step 4: Synthesis of a true pyrimidine (orotate) by **DHO dehydrogenase**
- Step 5: Orotate is joined with a ribose-P to form orotidine-5'-phosphate
- The ribose-P donor is PRPP
- Step 6: **OMP decarboxylase** makes UMP


Garrett & Grisham: Biochemistry, 2/e
 Figure 27.17




Metabolic channeling




- Eukaryotic pyrimidine synthesis involves channeling and multifunctional polypeptides
- UDP is made from UMP, and UTP is made for UDP
- **CTP synthetase** forms CTP from UTP and ATP




Garrett & Grisham: Biochemistry, 2/e
Figure 27.18



Garrett & Grisham: Biochemistry, 2/e
Figure 27.19








Deoxyribonucleotide Biosynthesis

- Reduction at 2'-position commits nucleotides to DNA synthesis
- Replacement of 2'-OH with hydride is catalyzed by **ribonucleotide reductase**
- An $\alpha_2\beta_2$ -type enzyme - subunits R₁ (86 kD) and R₂ (43.5 kD)
- R₁ has two regulatory sites, a **specificity site** and an **overall activity site**


Ribonucleotide Reductase

- Activity depends on Cys⁴³⁹, Cys²²⁵, and Cys⁴⁶² on R₁ and on Tyr¹²² on R₂
- Cys⁴³⁹ removes 3'-H, and dehydration follows, with disulfide formation between Cys²²⁵ and Cys⁴⁶²
- The net result is **hydride transfer** to C-2'
- Thioredoxin and thioredoxin reductase deliver reducing equivalents


Garrett & Grisham: Biochemistry, 2/e
Figure 27.22




Garrett & Grisham: Biochemistry, 2/e
Figure 27.23





Garrett & Grisham: Biochemistry, 2/e
Figure 27.24




Garrett & Grisham: Biochemistry, 2/e
Figure 27.25



Reduced glutathione (γ -glutamylcysteinylglycine, GSH)



Oxidized glutathione (GSSG) or glutathione disulfide




Regulation of dNTP Synthesis

- The overall activity of ribonucleotide reductase must be regulated
- Balance of the four deoxynucleotides must be controlled
- ATP activates, dATP inhibits at the overall activity site
- ATP, dATP, dTTP and dGTP bind at the specificity site to regulate the selection of substrates and the products made

Energy status of cell is robust; [ATP] is high. Make DNA:

- 1 ATP occupies activity site A: ribonucleotide reductase *ON*
- 2 ATP in specificity site S favors CDP or UDP in catalytic site C \longrightarrow [dCDP], [dUDP] \uparrow
- 3 $\left. \begin{array}{l} \text{dCDP} \\ \text{dUDP} \end{array} \right\} \longrightarrow \longrightarrow \text{dUMP} \longrightarrow \text{dTMP} \longrightarrow \longrightarrow \text{dTTP}$
- 4 dTTP occupies specificity site S, favoring GDP or ADP in catalytic site C
GDP \longrightarrow dGDP \longrightarrow dGTP
- 5 dGTP occupies specificity site S, favoring ADP in catalytic site C \longrightarrow [dADP] \uparrow
- 6 dATP replaces ATP in activity site A: ribonucleotide reductase *OFF*


Garrett & Grisham: Biochemistry, 2/e
Figure 27.27




Synthesis of Thymine Nucleotides


- Thymine nucleotides are made from **dUMP**, which derives from dUDP, dCDP
- dUDP → dUTP → dUMP → dTMP
- dCDP → dCMP → dUMP → dTMP
- **Thymidylate synthase** methylates dUMP at 5-position to make dTMP
- N⁵,N¹⁰-methylene THF is 1-C donor
- Note role of 5-FU in chemotherapy

Garrett & Grisham: Biochemistry, 2/e
Figure 27.28



Garrett & Grisham: Biochemistry, 2/e
Figure 27.29







2-Amino, 4-amino analogs of folic acid

R = H Aminopterin


R = CH₃ Amethopterin (methotrexate)




Trimethoprim







5-Flourouracil



5-Fluorocytosine



5-Fluoroorotate



Ternary complex